Reducing the risks of sudden death and heart failure post myocardial infarction: Utility of optimized pharmacotherapy

Clinical Cardiology

Volumn 28, Issue SUPPL., 2005, Pages 19-27

  Sackner Bernstein, Jonathan ^a  

^a NONE

Author keywords

ACE; Aldostertone antagonist; Angiotensin receptor blocker; Angiotensin converting enzyme inhibitor; ARB; Beta blocker; Statin

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; APOLIPOPROTEIN E; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CANDESARTAN; CAPTOPRIL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIN; EPLERENONE; FIBRINOLYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL; METOPROLOL TARTRATE; PERINDOPRIL; PRAVASTATIN; PROPRANOLOL; RAMIPRIL; ROSUVASTATIN; SIMVASTATIN; SPIRONOLACTONE; TIMOLOL; TRANDOLAPRIL; VALSARTAN;

CLINICAL PRACTICE; CLINICAL TRIAL; DIAGNOSTIC VALUE; DRUG EFFICACY; ELECTROLYTE DISTURBANCE; HEALTH CARE QUALITY; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE INFARCTION; HUMAN; KIDNEY DYSFUNCTION; LIFESTYLE; META ANALYSIS; OXIDATION; PATIENT COMPLIANCE; PATIENT EDUCATION; PRACTICE GUIDELINE; REVIEW; RISK BENEFIT ANALYSIS; SUDDEN DEATH; SYSTEMATIC REVIEW;

EID: 27744459664     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960281305     Document Type: Review

References (72)

1. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr, Alpert JS, Anderson JL, Faxon DR Fuster V, Gibbons RJ, Gregoratos G, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 2004:110:588-636
2. National Heart, Lung and Blood Institute: Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Full Report (NIH Publication No. 02-5215). Available at: http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3ftill.pdf. Accessed October 7, 2005,
3. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). J Am Med Assoc 2001:285:2486-2497
4. American Heart Association: Heart Disease and Stroke Statistics-2003 Update.. Available at: http://www.americanheart.org/downloadable/heart/ 1040391091015HDS_Stats_03.pdf. Accessed February 14, 2003, 2003
5. Walsh J: True Odds: How Risk Affects Your Everyday Life. Santa Monica, Calif.: Merritt Publishing, 1996
6. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM, Cutler JA, Windhauser MM, Lin PH, Karanja N: A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 1997:336:1117-1124
7. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, Obarzanek E, Conlin PR, Miller ER III, Simons-Morton DG, Karanja N, Lin PH: Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001:344:3-10
8. Ornish D, Scherwitz LW, Billings JH, Brown SE, Gould KL, Merritt TA, Sparler S, Armstrong WT, Ports TA, Kirkeeide RL, Hogeboom C, Brand RJ: Intensive lifestyle changes for reversal of coronary heart disease. J Am Med Assoc 1998:280:2001-2007
9. Paffenbarger RS Jr, Hyde RT, Wing AL, Lee IM, Jung DL, Kampert JB: The association of changes in physical-activity level and other lifestyle characteristics with mortality among men. N Engl J Med 1993:328:538-545
10. Stampfer MJ, Hu FB, Manson JE, Rimm EB, Willett WC: Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med 2000:343:16-22
11. Davies MJ, Thomas A: Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med 1984:310:1137-1140
12. Uretsky BF, Thygesen K, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Packer M, Poole-Wilson PA, Ryden L: Acute coronary findings at autopsy in heart failure patients with sudden death: Results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation 2000:102:611-616
13. Luu M, Stevenson WG, Stevenson LW, Baron K, Waiden J: Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. Circulation 1989:80:1675-1680
14. Farb A, Burke AP, Tang AL, Liang TY, Mannan P, Smialek J, Virmani R: Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Circulation 1996:93:1354-1363
15. Meischke H, Larsen MP, Eisenberg MS: Gender differences in reported symptoms for acute myocardial infarction: Impact on pre-hospital delay time interval. Am J Emerg Med 1998:16:363-366
16. Herlitz J, Bang A, Karlson BW, Hartford M: Is there a gender difference in aetiology of chest pain and symptoms associated with acute myocardial infarction? Eur J Emerg Med 1999:6:311-315
17. Kostuk WJ, Kazamias TM, Gander MP, Simon AL, Ross J Jr: Left ventricular size after acute myocardial infarction. Serial changes and their prognostic significance. Circulation 1973:47:1174-1179
18. Udelson JE, Konstam MA: Relation between left ventricular remodeling and clinical outcomes in heart failure patients with left ventricular systolic dysfunction. J Card Fail 2002:8:S465-S471
19. Migrino RQ, Young JB, Ellis SG, White HD, Lundergan CF, Miller DP, Granger CB, Ross AM, Califf RM, Topol EJ: End-systolic volume index at 90 to 180 minutes into reperfusion therapy for acute myocardial infarction is a strong predictor of early and late mortality. The Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I Angiographic Investigators. Circulation 1997:96:116-121
20. St John Sutton M, Pfeffer MA, Moyé L, Plappert T, Rouleau JL, Lamas G, Rouleau J, Parker JO, Arnold MO, Sussex B, Braunwald E: Cardiovascular death and left ventricular remodeling two years after myocardial infarction: Baseline predictors and impact of long-term use of captopril: Information from the Survival and Ventricular Enlargement (SAVE) trial. Circulation 1997:96:3294-3299
21. The GUSTO Investigators: An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993:329:673-682
22. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Beider R, Joyal SV, Hill KA, Pfeffer MA, Skene AM: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004:350:1495-1504
23. Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, Cohen EA, Bertrand M, Neumann FJ, Stone GW, DiBattiste PM, Demopoulos L: Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001:344:1888-1894
24. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A, Skene A: Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): Randomised controlled trial. Lancet 2003:362:7-13
25. The Beta-Blocker Evaluation of Survival Trial Investigators: A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001:344:1659-1667
26. Fennessy PA, Campbell JH, Campbell GR: Perindopril inhibits both the development of atherosclerosis in the cholesterol-fed rabbit and lipoprotein binding to smooth muscle cells in culture. Atherosclerosis 1994:106:29-41
27. Fox KM: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003:362:782-788
28. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000:342:145-153
29. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival And Ventricular Enlargement trial. The SAVE Investigators. N Engl J Med 1992:327:669-677
30. Captopril Multicenter Research Group: A placebo-controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol 1983:2:755-763
31. Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC: A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995:333:1670-1676
32. The SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992:327:685-691
33. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991:325:293-302
34. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H: Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II(CONSENSUS II). N Engl J Med 1992:327:678-684
35. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003:349:1893-1906
36. Cohn JN, Tognoni G: A randomized (rial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001:345:1667-1675
37. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme. Lancet 2003:362:759-766
38. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiolensin-converting-enzyme inhibitors: The CHARM-Added trial. Lancet 2003:362:767-771
39. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Ferez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart, failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999:341:709-717
40. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M: Eplerenone, a selective aldosterone blocker, in patients with lift ventricular dysfunction aftermyocardial infarction. N Engl J Med 2003:348:1309-1321
41. Rajagopalan S, Duquaine D, King S, Pitt B, Patel P: Mineral-ocorticoid receptor antagonism in experimental atherosclerosis. Circulation 2002:105:2212-2216
42. KeidarS, Kaplan M, Pavlotzky E, Cokman R, Hayek T, Hamoud S, Aviram M: Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: A possible role for angiotensin-converdng enzyme and the receptors for angiotensin II and aldosterone. Circulation 2004;109:2213-2220
43. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J, Albers JJ: Simvastatin and niacin, antioxidant vitamins, orthe combination for the prevention of coronary disease. N Engl J Med 2001:345:1583-1592
44. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. J Am Med Assoc 2004:291:1071-1080
45. Garcia PJ: Pleiotropic effects of statins: Moving beyond cholesterol control. Curr Atheroscler Rep 2005:7:34-39
46. Pitt B, Waters D, Brown WV, van Bovun AJ, Schwartz L, Title LM, Eisenberg D, Shurzinske L, McCormick LS: Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med 1999:341:70-76
47. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 2003:361:1149-1158
48. Colhoun HM, Betteridge DJ, Dumngton PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet 2004:364:685-696
49. The Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease; The Scandinavian Simvastatin Survival Study (4S). Lancet 1994:344:1383-1389
50. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002:360:7-22
51. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995:333:1301-1307
52. Sacks FM, Pfeffer MA, Moyé LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996:335:1001-1009
53. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998:339:1349-1357
54. Serruys PW, de Feyter P, Macaya C, Kokott N, Fuel J, Vrolix M, Branzi A, Bertolami MC, Jackson G, Strauss B, Meier B: Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: A randomized controlled trial. J Am Med Assoc 2002:287:3215-3222
55. Kjekshus J, Pedersen TR, Olsson AG, Faergeman O, Pyorala K: The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail 1997:3:249-254.
56. Erratum in: J Card Fail 1998:4:367
57. Madonna R, Di Napoli P, Massaro M, Grilli A, Felaco M, De Caterina A, Tang D, De Caterina R, Geng YJ: Simvastatin attenuates expression of cytokine-inducible nitric-oxide synthase in embryonic cardiac myoblasts. J Biol Chem 2005:280:13503-13511
58. Whittington-Coleman PJ, Carrier O Jr, Douglas BH: The effects of propranolol on cholesterol-induced atheromatous lesions. Atherosclerosis 1973:18:337-345
59. Chobanian AV, Brecher P, Chan C: Effects of propranolol on atherogenesis in the cholesterol-fed rabbit. Circ Res 1985:56:755-762
60. Yue TL, Wang X, Gu JL, Ruffolo RR Jr, Feuerstein GZ: Carvedilol prevents low-density lipoprotein (LDL)-enhanced monocyte adhesion to endothelial cells by inhibition of LDL oxidation. Eur J Pharmacol 1995:294:585-591
61. Beta-blocker Heart Attack Trial Research Group: A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. J Am Med Assoc 1982:247:1707-1714
62. The Norwegian Multicenter Study Group: Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981:304:801-807
63. First International Study of Infarct Survival Collaborative Group: Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 1986:2:57-66
64. Hjalmarson A, Elmfeldt D, Herlitz J, Holmberg S, Malek I, Nyberg G, Ryden L, Swedberg K, Vedin A, Waagstein F, Waldenstrom A, Waldenstrom J, Wedel H, Wilhelmsen L, Wilhelmsson C: Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet 1981:2:823-827
65. The MIAMI Trial Research Group: First International Study of Infarct Survival Collaborative Group: Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. Eur Heart J 1985:6:199-226
66. Lopressor Intervention Trial Research Group: The Lopressor Intervention Trial: Multicentre study of metoprolol in survivors of acute myocardial infarction. Eur Heart J 1987:8:1056-1064
67. Dargie HJ: Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomised trial. Lancet 2001:357:1385-1390
68. CIBIS-II Investigators and Committees: The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 1999:353:9-13
69. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schulte MK, DeMets DL: Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001:344:1651-1658
70. MERTT-HF Study Group: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999:353:2001-2007
71. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, Murabito JM, Vasan RS: Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002:347:1397-1402
72. Libby P: The forgotten majority: Unfinished business in cardiovascular risk reduction. J Am Coll Cardiol 2005:46:1225-1228